Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$32.8 million.

  • NewAmsterdam Pharma's Free Cash Flow fell 16088.1% to -$32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$144.5 million, marking a year-over-year increase of 664.67%. This contributed to the annual value of -$159.2 million for FY2024, which is 1273.98% down from last year.
  • As of Q3 2025, NewAmsterdam Pharma's Free Cash Flow stood at -$32.8 million, which was down 16088.1% from -$37.8 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Free Cash Flow registered a high of -$12.6 million during Q3 2024, and its lowest value of -$55.0 million during Q1 2024.
  • Its 3-year average for Free Cash Flow is -$37.8 million, with a median of -$37.0 million in 2024.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 7323.19% in 2024, then tumbled by 16088.1% in 2025.
  • Over the past 3 years, NewAmsterdam Pharma's Free Cash Flow (Quarter) stood at -$33.1 million in 2023, then dropped by 13.32% to -$37.5 million in 2024, then increased by 12.47% to -$32.8 million in 2025.
  • Its Free Cash Flow stands at -$32.8 million for Q3 2025, versus -$37.8 million for Q2 2025 and -$36.5 million for Q1 2025.